Table 3.

Aortic Volume With ^99mTc-Tilmanocept Uptake Across Different Thresholds in Relation to Aortic Noncalcified Plaque Volume

99mTc-Tilmanocept Uptake Threshold	Participants With HIVa (n = 18)			Participants Without HIVb (n = 9)
	R 2	β-Estimate	P Value	R 2	β-Estimate	P Value
3× muscle activity	0.46	64.8	.002	0.008	9.0	.81
3.5× muscle activity	0.43	57.4	.003	0.0001	−1.0	.98
4× muscle activity	0.41	49.5	.004	0.009	−6.8	.81
4.5× muscle activity	0.43	42.8	.003	0.03	−7.0	.68
5× muscle activity	0.44	34.1	.003	0.08	−7.6	.45
5.5× muscle activity	0.44	25.9	.003	0.05	−3.1	.56
6× muscle activity	0.44	19.5	.003	0.14	−2.4	.32

R ², β-estimate, and P value from simple (bivariate) linear regression modeling at the indicated uptake threshold and HIV status, with ^99mTc-tilmanocept uptake as the dependent variable and aortic noncalcified volume as the independent variable. Bivariate regression analyses results for the aortic noncalcified volume with Hounsfield unit <130 are shown. P values <.05 were considered significant and are bolded.

Abbreviations: ^99mTc, 99m-technetium; HIV, human immunodeficiency virus.

^aOne participant with HIV was not included because his total aortic plaque volume was 4 standard deviations above the median total aortic plaque volume among participants with HIV. Another participant with HIV was not included because he had high levels of ^99mTc-tilmanocept uptake, which were thought to be likely due to decreased hepatic clearance.

^bOne participant without HIV did not complete his computed tomography angiography and thus did not have aortic plaque volume data available.